Dose‐dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship

Publisher： John Wiley & Sons Inc

E-ISSN： 1528-1167|56|6|924-932

ISSN： 0013-9580

Source： EPILEPSIA, Vol.56, Iss.6, 2015-06, pp. : 924-932

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Characterizing the PK/PD relationship for inhibition of capsaicin‐induced dermal vasodilatation by MK‐3207, an oral calcitonin gene related peptide receptor antagonist

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 79, Iss. 5, 2015-05 ,pp. : 831-837

John Wiley & Sons Inc

Access to resources Recommend Favorite

PKPD modelling to predict altered disposition of 1α,25‐dihydroxyvitamin D3 in mice due to dose‐dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 14, 2015-07 ,pp. : 3611-3626

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prediction of Clinical Irrelevance of PK Differences in Atorvastatin Using PK/PD Models Derived From Literature‐Based Meta‐Analyses

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 1, 2014-07 ,pp. : 101-109

John Wiley & Sons Inc

Access to resources Recommend Favorite

Population PK Analyses of Ubrogepant (MK‐1602), a CGRP Receptor Antagonist: Enriching In‐Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 58, Iss. 3, 2018-03 ,pp. : 294-303

John Wiley & Sons Inc

Access to resources Recommend Favorite

The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist

By  

EPILEPSIA, Vol. 56, Iss. 1, 2015-01 ,pp. : 12-27

John Wiley & Sons Inc

Access to resources Recommend Favorite